Pete received his BSc (Hons) in Biomedical Sciences – Neuroscience and PhD in Visual Neuroscience and Molecular Biology from Cardiff University, Wales under the mentorship of Profs. James Morgan and Marcela Votruba before undertaking his postdoctoral training in the laboratory of HHMI investigator Prof. Simon WM John at The Jackson Laboratory, ME, USA. Pete is an Assistant Professor in Medical Sciences in the Dept. of Clinical Neuroscience, Section of Ophthalmology and Vision at the Karolinska Institutet and a Research Group Leader at S:t Eriks Ögonsjukhus (St Erik Eye Hospital). Current C.V. [pdf]
James Tribble, PhD – Postdoctoral Researcher
James received his BSc (Hons) in Medical Pharmacology and PhD in Visual Neuroscience and Molecular Biology from Cardiff University, Wales before undertaking his initial postdoctoral training in the lab of Prof. James Morgan at the School of Optometry and Vision Sciences, Cardiff University where his work has focused on early dendrite and synapse refinement during glaucoma using human patient and glaucoma animal model tissues. James joined the Pete Williams Lab in 2018 to further his postdoctoral education where his work focuses on the early mechanisms in glaucoma and treatments that intersect these mechanisms. Current C.V. [pdf]
James Morgan, MB BCh MA DPhil FRCOphth – Visiting Researcher
James E Morgan is Professor of Ophthalmology at Cardiff University and Honorary Consultant Ophthalmologist at the University Hospital of Wales, UK. He also holds an appointment at the School of Optometry and Vision Sciences, Cardiff University.
He read Medical Sciences at Cambridge University followed by a PhD in Visual Neuroscience at Oxford University studying the development of visual pathways and their connections in the central nervous system. He studied medicine at the University of Oxford and then trained in Ophthalmology at Oxford, London (Moorfields) and Bristol. In 1994 he was a Medical Research Council Training Fellow at the Department of Ophthalmology, Yale University, USA working on models of retinal ganglion cell death in experimental glaucoma.
He took up his appointment at Cardiff in 1997 and established a research group interested in imaging techniques for the detection of retinal damage in disease and in the use of laboratory research to understand the pathophysiology of retinal damage in glaucoma. He has promoted the use of Open Source informatics to support the translation of novel technologies in eye care. He was the Chief Clinical Information Officer at Moorfields Eyes Hospital 2014-2016. He currently chairs the OpenEyes Foundation to support the development of OpenEyes, the leading open source electronic patient record for ophthalmology in the UK.
Marcela Votruba, BM BCh MA PhD FRCOphth FLSW – Visiting Researcher
Marcela Votruba is Professor of Ophthalmology at Cardiff University and Honorary Consultant Ophthalmologist at the University Hospital of Wales, UK. She has been the Head of the School of Optometry & Vision Sciences at Cardiff University since Jan 2014. Previously she was a Consultant Ophthalmologist at Moorfields Eye Hospital.
She read Physiological Sciences at Oxford University and trained at the Oxford Medical School, followed by training in ophthalmology at Bristol and Moorfields Eye Hospitals. Her Wellcome Trust Vision Research Training fellowship funded PhD in Human Molecular Genetics was at UCL Institute of Ophthalmology in the lab of Professor Shomi Bhattacharya and at Moorfields Eye Hospital under Professor Tony Moore. In 2000 her early-career research team at UCL Institute of Ophthalmology published the first paper identifying the gene OPA1 causing familial optic atrophy. She moved to Cardiff in 2003 in order to take up an MRC Clinician Scientist Fellowship to study the role of mitochondrial fusion and fission genes in the pathophysiology of optic neuropathy. She has continued to publish work on the pathophysiological mechanisms underlying blindness due to retinal ganglion cell loss in mitochondrial optic neuropathy. Her recent research has focused on developing new translational therapeutic interventions and both pre-clinical and clinical trials.